Related Experiment Video
Updated: Sep 11, 2025
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
Proton Pump Inhibitor Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and
Hasan Jaber1, Sandra Chehayeb1, Janane Nasr1
1University of Kansas School of Medicine, Internal Medicine Department, Wichita, KS.
Background:
Hepatic encephalopathy (HE) is a debilitating complication of liver cirrhosis, characterized by neuropsychiatric symptoms ranging from mild cognitive impairment to coma. Proton pump inhibitors (PPIs) are widely used in cirrhotic patients for managing gastrointestinal conditions. However, emerging evidence has suggested a potential link between PPI use and HE, possibly due to increased intestinal permeability and bacterial translocation.
Objective:
To evaluate and synthesize current evidence on the association between PPI use and the risk of hepatic encephalopathy in patients with liver cirrhosis through a systematic review and meta-analysis.
Methods:
A total of 22 studies were included in this systematic review and meta-analysis, comprising both case-control and cohort designs. Hazard ratios (HRs) and odds ratios (ORs) were used to quantify the association between PPI use and the development of HE.
Results:
The initial pooled analysis showed that PPI use was associated with an increased risk of HE, with a hazard ratio (HR) of 1.59 (95 % CI: 1.42-1.77) and an odds ratio (OR) of 2.07 (95 % CI: 1.57-2.72; I² = 96.4 %, p < 0.0001). In the OR group, a subgroup analysis by study type showed: Case-control studies: OR = 2.29 (95 % CI: 1.46-3.59, I² = 76.9 %, p < 0.0017). Retrospective cohort studies: OR = 1.107 (95 % CI: 1.05-1.166, I² = 0 %, p = 0.97). Nardelli et al. and Sun et al. were not pooled as they were prospective cohort studies. In the HR group, all included studies were retrospective cohort studies, so no further subgroup analysis was performed. After excluding high-risk studies/abstracts, the pooled HR was 1.49 (95 % CI: 1.266-1.743, I² = 37.9 %, p = 0.153).
Conclusion:
This meta-analysis supports a potential association between PPI use and an increased risk of hepatic encephalopathy in cirrhotic patients. These findings underscore the importance of cautious and judicious use of PPIs in this vulnerable population, reserving them for clear clinical indications.
Related Concept Videos
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:09Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...